Treatment of relapsed acute myelogeneous leukaemia with MLL/AF 6 fusion after stem cell transplantation by intensive reinduction followed by adoptive immunotherapy.
Schuster
F R
FR
Führer
M
M
Woessmann
W
W
Reiter
A
A
Harbott
J
J
Viehmann
S
S
Borkhardt
A
A
D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000276:immunology / Q000627:therapeutic use*; D002648:Child; D002896:Chromosomes, Human, Pair 6 / Q000235:genetics*; D005260:Female; D006086:Graft vs Host Disease / Q000209:etiology; D006801:Humans; D016219:Immunotherapy, Adoptive; D015470:Leukemia, Myeloid, Acute / Q000188:drug therapy* / Q000235:genetics / Q000276:immunology; D008297:Male; D009181:Mycoses / Q000209:etiology; D051788:Myeloid-Lymphoid Leukemia Protein; D015514:Oncogene Proteins, Fusion / Q000235:genetics*; D012333:RNA, Messenger / Q000235:genetics; D012008:Recurrence; D012074:Remission Induction; D033581:Stem Cell Transplantation
C447400:MLL-AF6 fusion protein, human; D015514:Oncogene Proteins, Fusion; D012333:RNA, Messenger; D051788:Myeloid-Lymphoid Leukemia Protein